Rachel McMinn

Rachel McMinn

Directeur Général chez
Neurogene, Inc.

Fortune : 37 M $ au 30/09/2026

53 ans
Finance
Health Technology
Consumer Services

Profil

Rachel L.
McMinn
is the founder of Neurogene OpCo., founded in 2018, serving as Chief Executive Officer since 2019.
Dr. McMinn is the founder of Neurogene, Inc., founded in 2018, serving as Executive Chairman & Chief Executive Officer since 2023.
Dr. McMinn is currently Director at EveryONE Medicines, Inc. since 2021.
Former positions include Director at Cowen & Co. LLC.
from 2007 to 2009, Senior Analyst at Piper Sandler & Co. (Broker), Chief Business & Strategy Officer at Intercept Pharmaceuticals, Inc. from 2014 to 2017, Principal at Banc of America Securities LLC in 2009, Analyst at Piper Sandler & Co., and Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. Education includes a doctorate from The Scripps Research Institute and an undergraduate degree from Cornell University.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
6,72 %
22/09/2026 1 345 063 ( 6,72 % ) 37 M $ 30/09/2026

Postes actifs de Rachel McMinn

SociétésPosteDébut
Directeur Général 01/01/2018
Directeur/Membre du Conseil 01/01/2021

Anciens postes connus de Rachel McMinn

SociétésPosteFin
INTERCEPT PHARMACEUTICALS, INC. Corporate Officer/Principal 01/12/2017
Analyst-Equity 30/04/2009
Analyst-Equity 31/03/2009
Analyst-Equity 31/12/2006
Corporate Officer/Principal -
Voir l'expérience en détail de Rachel McMinn

Formation de Rachel McMinn

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

62

Relations au 1er degré

10

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées10

Finance

Finance

Health Technology

Consumer Services

Finance

Consumer Services

Finance

Finance

Health Technology

Commercial Services

  1. Bourse
  2. Insiders
  3. Rachel McMinn
🔇